Study Details
CABL001I12201: A Study Drug for Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
(IRB#: IRB_00158588)
Philadelphia chromosome-positive chronic myeloid leukemia is a disease that causes abnormal changes to the chromosomes leading to high levels of abnormal cells in the bone marrow and blood. CABL001I12201 is a study drug for children with this disease. Research is needed to learn the safety and effectiveness of the study drug. The information we gain may aid future patients.
- All genders
- Under 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 1 to 18 years old
- Specific levels of bone marrow and blood counts at the first study visit
- Prior treatment with a minimum of one Tyrosine kinase inhibitor (TKI)
- Prior treatment with a minimum of one Tyrosine kinase inhibitor (TKI)
- Attend a University of Utah
Exclusion Criteria
- Current or history of specific heart diseases
- Planning to have allogeneic hematopoietic stem cell transplantation
- Previous treatment with hematopoietic stem-cell transplantation.
Will I be paid for my time?
Yes
IRB#: IRB_00158588
PI: Mallorie Heneghan
Department: PEDIATRICS
Approval Date: 2023-04-05 06:00:00
Specialties: Pediatric Hematology & Oncology